Author

E. Lheriteau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Organism:non-human primate· 1 Organism:plant (other)· 1

Frequent Co-Authors

B. Vanhove· 4 shared C. Ciron· 4 shared G. Evanno· 4 shared O. Duvaux· 4 shared P.-J. Royer· 4 shared J. Rousse· 3 shared A. Perota· 2 shared A. Salama· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

B. Vanhove

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation

J. Rousse, P.-J. Royer, G. Evanno, E. Lheriteau, C. Ciron, A. Salama, F. Shneiker, R. Duchi, A. Perota, C. Galli, E. Cozzi, G. Blancho, O. Duvaux, S. Brouard, J.-P. Soulillou, , B. Vanhove

The paper describes LIS1, a glyco-humanized anti-lymphocyte globulin, as a novel induction therapy for solid organ transplantation that reduces immunogenicity and T-cell depletion while maintaining immunosuppression.

bioRxiv · Sep 8, 2022Immunology

Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron)

B. Vanhove, S. S. Marot, G. Evanno, I. Mallet, G. Rouvray, F. Shneiker, E. Mevel, C. Ciron, J. Rousse, P.-J. Royer, E. Lheriteau, F. Raffi, O. Duvaux, A.-G. Marcelin, V. Calvez

bioRxiv · Jan 26, 2022 · PreprintImmunology

XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants.

B. Vanhove, S. S. Marot, R. So, B. Gaborit, G. Evanno, I. Malet, G. Lafrogne, E. Mevel, C. Ciron, P.-J. Royer, E. Lheriteau, F. Raffi, R. Bruzzone, C. K. P. Mok, O. Duvaux, , V. Calvez

XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 Spike RBD, neutralizes multiple variants by targeting multiple epitopes and shows potential in clinical trials.

bioRxiv · Apr 2, 2021Immunology

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

B. Vanhove, O. Duvaux, J. Rousse, P.-J. Royer, G. Evanno, C. Ciron, E. Lheriteau, L. Vacher, N. Gervois, R. Oger, Y. Jacques, S. Conchon, A. Salama, R. Duchi, I. Lagutina, , J.-P. Soulillou

This paper describes the development of glyco-humanized swine polyclonal antibodies (GH-pAb) that neutralize SARS-CoV-2 with high potency and safety, and suggests clinical evaluation of the antibody XAV-19.

bioRxiv · Jul 25, 2020Immunology